These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 11098494)
1. UFT/leucovorin plus vinorelbine combination for advanced breast cancer. Fumoleau P; Déporte R; Kerbrat P; Bonneterre J; Fargeot P Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):50-5. PubMed ID: 11098494 [TBL] [Abstract][Full Text] [Related]
2. UFT plus oral calcium folinate/vinorelbine for advanced breast cancer. Fumoleau P; Déporte-Fety R; Kerbrat P; Laguerre B Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):86-90. PubMed ID: 10442371 [TBL] [Abstract][Full Text] [Related]
3. Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Urien S; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Deporte-Fety R Cancer Chemother Pharmacol; 2003 Aug; 52(2):99-107. PubMed ID: 12768319 [TBL] [Abstract][Full Text] [Related]
4. A phase I study of UFT-oral vinorelbine in metastatic breast cancer. Ferrero JM; Largillier R; Michel C; Amiot V; Milano G; Hébert C; Mari V; Courdi A; Figl A; Follana P; Barrière J; Chamorey E Oncology; 2011; 81(2):73-8. PubMed ID: 21968516 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535 [TBL] [Abstract][Full Text] [Related]
6. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. Price T; Hill M Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487 [TBL] [Abstract][Full Text] [Related]
7. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule. Pazdur R; Lassere Y; Diaz-Canton E; Ho DH Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627 [TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. Hortobagyi GN; Heim W; Hutchins L; Rivera E; Mason B; Booser DJ; Kirshner J Cancer; 2010 Mar; 116(6):1440-5. PubMed ID: 20091835 [TBL] [Abstract][Full Text] [Related]
9. A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer. Scholz U; Lück HJ; Canzler U; Robner D; Kühnle H Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):44-6. PubMed ID: 11098492 [TBL] [Abstract][Full Text] [Related]
10. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614 [TBL] [Abstract][Full Text] [Related]
11. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Damle B; Ravandi F; Kaul S; Sonnichsen D; Ferreira I; Brooks D; Stewart D; Alberts D; Pazdur R Clin Cancer Res; 2001 Mar; 7(3):517-23. PubMed ID: 11297242 [TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. Pazdur R Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):35-9. PubMed ID: 9348565 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design. Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772 [TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Hortobagyi GN; Young RR; Karwal M; Ibrahim NK; Hermann R; Murray JL; Watkins SP; Gore I Cancer; 2010 May; 116(10):2301-6. PubMed ID: 20225231 [TBL] [Abstract][Full Text] [Related]
15. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552 [TBL] [Abstract][Full Text] [Related]
16. UFT plus oral folinic acid with alternating oral and intravenous vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Coşkun U; Kaya AO; Alkis N; Buyukberber S; Alici S; Celenkoglu G; Uncu D; Ozkan M; Sevinc A; Benekli M Onkologie; 2009 Oct; 32(10):562-6. PubMed ID: 19816072 [TBL] [Abstract][Full Text] [Related]
17. Irinotecan and UFT/leucovorin in patients with advanced cancers. Stevenson JP; Redlinger M; Sun W; Haller D; O'Dwyer PJ Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):91-2. PubMed ID: 11098504 [TBL] [Abstract][Full Text] [Related]
18. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Hoff PM; Pazdur R; Benner SE; Canetta R Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235 [TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer. Klaassen U; Borquez D; Lang S; Oberhoff C; Harstrick A; Seeber S; Benner S Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):71-3. PubMed ID: 10442367 [TBL] [Abstract][Full Text] [Related]
20. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]